LY2562175 Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

540.44

DMSO: 62.5mg/mL (115.65mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)

C28H27Cl2N3O4

O=C(C1=CN(C)C2=C1C=CC(N3CCC(OCC4=C(C5CC5)ON=C4C6=C(Cl)C=CC=C6Cl)CC3)=C2)O

1103500-20-4

FXR: ic50 193nM (EC50)

LY2562175 induces a dose-dependent decrease in serum cholesterol and serum triglycerides. LY2562175(female ZDF rats) treatment, causes a dose-dependent lowering of plasma triglycerides in the fasted and nonfasted states. LY2562175 further lowers fasted and nonfasted plasma triglycerides when administered as a fixed-dose combination with BRL49653. At a dose of 10mg/kg, the decrease in cholesterol with LY2562175 is 80% below vehicle-treated animals, and the decrease in serum triglycerides is 76% from the control group. The ED50 for serum cholesterol is determined to be 2 and 3.4mg/kg for serum triglycerides. FPLC fractionation of the lipoproteins shows that LY2562175 treatment, causes a reduction in vLDL-C and a dramatic increase in HDL-c in this animal model.